The Pharmacy Times® Pain Management resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, among other items that pharmacists will find valuable.
What can we help you find?
More than 90% of the legal marijuana products offered in medical dispensaries are much stronger than what physicians typically recommend for chronic pain relief via data from clinical studies, according to research published in PLOS ONE.
RedHill Biopharma Ltd today announced that it has completed the recently announced acquisition of the global rights to Movantik (naloxegol) for the treatment of opioid-induced constipation (OIC) from AstraZeneca.
A new study examining records from the Ohio Health Department from 2010 to 2017 found that white men between the ages of 30 and 39 had the highest risk for fatal opioid overdoses.
The research showed that the preventive effect of eptinezumab-jjmr was statistically significant versus placebo as early as day 1 and maintained throughout 3 months post-infusion.
The FDA has released a statement addressing the issue, stating that the organization is “not aware of scientific evidence connecting the use of NSAIDs, like ibuprofen, with worsening COVID-19 symptoms.”
Patients who received an opioid after tooth extraction reported higher levels of pain than patients who received a non-opioid.
Better, evidence-based treatments exist for this common condition, which can cause disability.
This approval marks the first for combination ibuprofen and acetaminophen for OTC use.
This is one of the first US population-based studies to compare overdose risk among 2 patient populations across an entire state.
In recent years, drugmakers have been accused of pushing opioid prescriptions on physicians across the United States and allegedly downplaying the risks of addiction. Meanwhile, governments feel that distributors and pharmacies have turned a blind eye to suspicious orders and failed to meet government requirements on painkillers.
The new drug is a nonopioid therapeutic option for patients experiencing moderate to severe pain.
Diclofenac sodium topical gel was first approved by the FDA in 2007 as a prescription drug, and was indicated for the relief of osteoarthritis pain in joints responsive to topical treatment, particularly the joints of the hands, knees, and feet.